T2 Biosystems Statistics
Share Statistics
T2 Biosystems has 21.04M shares outstanding. The number of shares has increased by 331.57% in one year.
| Shares Outstanding | 21.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 13.76% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 9.34M |
| Failed to Deliver (FTD) Shares | 41.49K |
| FTD / Avg. Volume | 5.79% |
Short Selling Information
The latest short interest is 834.76K, so 3.97% of the outstanding shares have been sold short.
| Short Interest | 834.76K |
| Short % of Shares Out | 3.97% |
| Short % of Float | 12% |
| Short Ratio (days to cover) | 1.26 |
Valuation Ratios
The PE ratio is -0.33 and the forward PE ratio is -0.45.
| PE Ratio | -0.33 |
| Forward PE | -0.45 |
| PS Ratio | 2.28 |
| Forward PS | 0.3 |
| PB Ratio | -0.58 |
| P/FCF Ratio | -0.34 |
| PEG Ratio | n/a |
Enterprise Valuation
T2 Biosystems Inc. has an Enterprise Value (EV) of 50.20M.
| EV / Earnings | -1 |
| EV / Sales | 6.98 |
| EV / EBITDA | -1.14 |
| EV / EBIT | -1.01 |
| EV / FCF | -1.04 |
Financial Position
The company has a current ratio of 0.45, with a Debt / Equity ratio of -1.53.
| Current Ratio | 0.45 |
| Quick Ratio | 0.36 |
| Debt / Equity | -1.53 |
| Total Debt / Capitalization | 288.62 |
| Cash Flow / Debt | -1.12 |
| Interest Coverage | -9.3 |
Financial Efficiency
Return on equity (ROE) is 1.79% and return on capital (ROIC) is -231.4%.
| Return on Equity (ROE) | 1.79% |
| Return on Assets (ROA) | -1.44% |
| Return on Capital (ROIC) | -231.4% |
| Revenue Per Employee | 63.65K |
| Profits Per Employee | -443.16K |
| Employee Count | 113 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 3.19 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -90.43% in the last 52 weeks. The beta is 0.38, so T2 Biosystems 's price volatility has been higher than the market average.
| Beta | 0.38 |
| 52-Week Price Change | -90.43% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 3.2 |
| Relative Strength Index (RSI) | 28.38 |
| Average Volume (20 Days) | 716.99K |
Income Statement
In the last 12 months, T2 Biosystems had revenue of $7.19M and earned -$50.08M in profits. Earnings per share was $-19.19.
| Revenue | 7.19M |
| Gross Profit | -8.17M |
| Operating Income | -49.66M |
| Net Income | -50.08M |
| EBITDA | -43.88M |
| EBIT | -49.66M |
| Earnings Per Share (EPS) | -19.19 |
Balance Sheet
The company has $15.69M in cash and $49.50M in debt, giving a net cash position of -$33.81M.
| Cash & Cash Equivalents | 15.69M |
| Total Debt | 49.50M |
| Net Cash | -33.81M |
| Retained Earnings | -584.30M |
| Total Assets | 18.08M |
| Working Capital | -14.65M |
Cash Flow
In the last 12 months, operating cash flow was -$48.14M and capital expenditures -$192.00K, giving a free cash flow of -$48.33M.
| Operating Cash Flow | -48.14M |
| Capital Expenditures | -192.00K |
| Free Cash Flow | -48.33M |
| FCF Per Share | -18.52 |
Margins
Gross margin is -113.58%, with operating and profit margins of -690.45% and -696.19%.
| Gross Margin | -113.58% |
| Operating Margin | -690.45% |
| Pretax Margin | -696.19% |
| Profit Margin | -696.19% |
| EBITDA Margin | -609.97% |
| EBIT Margin | -690.45% |
| FCF Margin | -671.88% |
Dividends & Yields
TTOO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5330.56% |
| FCF Yield | -631.64% |
Analyst Forecast
The average price target for TTOO is $5, which is 1288.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 1288.9% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Oct 13, 2023. It was a backward split with a ratio of 1:100.
| Last Split Date | Oct 13, 2023 |
| Split Type | backward |
| Split Ratio | 1:100 |
Scores
| Altman Z-Score | -55.38 |
| Piotroski F-Score | 3 |